Related Experiment Video
Updated: Mar 21, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left
Mehmet Ozaydin1, Habil Yucel, Sule Kocyigit
1Department of Cardiology, Suleyman Demirel University, Isparta, Turkey.
Insights
Nebivolol use in acute myocardial infarction (AMI) patients with left ventricular dysfunction showed a lower rate of cardiovascular events compared to metoprolol succinate over 12 months. Carvedilol demonstrated similar outcomes to both nebivolol and metoprolol succinate.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Beta-blockers are crucial in managing acute myocardial infarction (AMI) with left ventricular dysfunction.
- Different beta-blockers may offer varying clinical benefits in post-AMI care.
Purpose of the Study:
- To compare the efficacy of nebivolol, carvedilol, and metoprolol succinate in patients with AMI and reduced left ventricular ejection fraction.
- To assess the impact of these beta-blockers on major adverse cardiovascular events over a 12-month period.
Main Methods:
- A randomized trial involving 172 patients with AMI and left ventricular ejection fraction ≤0.45.
- Patients were assigned to nebivolol (n=55), carvedilol (n=60), or metoprolol succinate (n=57) groups.
- Composite endpoints included nonfatal MI, cardiovascular death, heart failure/unstable angina hospitalization, stroke, or revascularization.
Main Results:
- Baseline characteristics were similar across all three treatment groups.
- Nebivolol significantly reduced the composite endpoint compared to metoprolol succinate (14.5% vs. 31.5%, p=0.03).
- Event rates were comparable between carvedilol and metoprolol succinate, and between nebivolol and carvedilol.
Conclusions:
- Nebivolol demonstrated superior efficacy in reducing 12-month cardiovascular events compared to metoprolol succinate in post-AMI patients with left ventricular dysfunction.
- Carvedilol showed similar efficacy to both metoprolol succinate and nebivolol in this patient population.
Objective:
The aim of this study was to evaluate the efficacy of nebivolol, carvedilol or metoprolol succinate on the outcome of patients presenting with acute myocardial infarction (AMI) complicated by left ventricular dysfunction.
Subjects And Methods:
Patients (n = 172, aged 28-87 years) with AMI and left ventricular ejection fraction ≤0.45 were randomized to the nebivolol (n = 55), carvedilol (n = 60) and metoprolol succinate (n = 57) groups. Baseline demographic and clinical characteristics and composite event rates of nonfatal MI, cardiovascular mortality, hospitalization due to unstable angina pectoris or heart failure, stroke or revascularization during the 12-month follow-up were compared among the groups using the x03C7;2 test, t test or log-rank test as appropriate.
Results:
Baseline demographic and clinical characteristics were similar in the three groups. The composite end point during follow-up was lower in the patients treated with nebivolol than those treated with metoprolol (14.5 vs. 31.5%; p = 0.03). However, event rates were similar between the patients treated with carvedilol and those treated with the metoprolol (20.3 vs. 31.5%, p > 0.05) and between the patients treated with nebivolol and carvedilol (14.5 vs. 20.3%, p > 0.05).
Conclusion:
The patients treated with nebivolol experienced 12-month cardiovascular events at a lower rate than those treated with metoprolol succinate. However, event rates were similar between the carvedilol and the metoprolol succinate groups and between the nebivolol and the carvedilol groups.
More Related Videos
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System